A method of identifying a patient likely to benefit from omega-3 fatty acid therapy for dementia, vascular dementia, Parkinson's dementia, Alzheimer's disease, and/or mild cognitive impairment includes identifying a patient having abnormal brain activity by conducting one or more baseline scans of the patient's brain, administering a first dosage regimen of omega-3 fatty acids to the patient so identified, thereafter conducting one or more assessment scans of the patient's brain, comparing the one or more assessment scans with the one or more baseline scans to determine any improvement in the patient's brain activity, and selecting any patient having an improvement in brain activity to receive omega-3 fatty acid therapy for the treatment or prevention of dementia, vascular dementia, Parkinson's dementia, Alzheimer's disease, and/or mild cognitive impairment. Another method of of identifying a patient likely to benefit from omega-3 fatty acid therapy for a brain disorder includes the steps of conducting a basal metabolic scan of the patient's brain, thereafter administering a stimulated perfusion dose of omega-3 fatty acids to the patient, conducting a stimulated perfusion scan of the patient's brain, and comparing the basal metabolic scan with the stimulated perfusion scan to differentially diagnose a brain disorder that is treatable with omega-3 fatty acids. Further included are methods of treating a patient identified as being likely to benefit from omega-3 fatty acid therapy, and diagnostic tests to identify such patients.
展开▼